TALS
NASDAQTalaris Therapeutics Inc.
Latest news
25 items- 13D/GSEC Form SC 13G/A filed by Talaris Therapeutics Inc. (Amendment)SC 13G/A - Tourmaline Bio, Inc. (0001827506) (Subject)
- 13D/GSEC Form SC 13G filed by Talaris Therapeutics Inc.SC 13G - Tourmaline Bio, Inc. (0001827506) (Subject)
- 13D/GSEC Form SC 13G/A filed by Talaris Therapeutics Inc. (Amendment)SC 13G/A - Tourmaline Bio, Inc. (0001827506) (Subject)
- 13D/GSEC Form SC 13G/A filed by Talaris Therapeutics Inc. (Amendment)SC 13G/A - Tourmaline Bio, Inc. (0001827506) (Subject)
- 13D/GSEC Form SC 13G/A filed by Talaris Therapeutics Inc. (Amendment)SC 13G/A - Tourmaline Bio, Inc. (0001827506) (Subject)
- 13D/GSEC Form SC 13G filed by Talaris Therapeutics Inc.SC 13G - Tourmaline Bio, Inc. (0001827506) (Subject)
- 13D/GSEC Form SC 13G/A filed by Talaris Therapeutics Inc. (Amendment)SC 13G/A - Tourmaline Bio, Inc. (0001827506) (Subject)
- INSIDERMcdade Mark bought $3,250,000 worth of shares (100,000 units at $32.50) (SEC Form 4)4 - Tourmaline Bio, Inc. (0001827506) (Issuer)
- SECTalaris Therapeutics Inc. filed SEC Form 8-K: Financial Statements and Exhibits8-K - Tourmaline Bio, Inc. (0001827506) (Filer)
- SECSEC Form 424B5 filed by Talaris Therapeutics Inc.424B5 - Tourmaline Bio, Inc. (0001827506) (Filer)
- SECSEC Form 424B5 filed by Talaris Therapeutics Inc.424B5 - Tourmaline Bio, Inc. (0001827506) (Filer)
- SECTalaris Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits8-K - Tourmaline Bio, Inc. (0001827506) (Filer)
- SECTalaris Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Tourmaline Bio, Inc. (0001827506) (Filer)
- INSIDERSEC Form 4 filed by Siegall Clay B4 - Tourmaline Bio, Inc. (0001827506) (Issuer)
- INSIDERSEC Form 3 filed by new insider Siegall Clay B3 - Tourmaline Bio, Inc. (0001827506) (Issuer)
- SECTalaris Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Tourmaline Bio, Inc. (0001827506) (Filer)
- SECTalaris Therapeutics Inc. filed SEC Form 8-K: Leadership Update8-K - Tourmaline Bio, Inc. (0001827506) (Filer)
- INSIDERKulkarni Sandeep Chidambar bought $67,960 worth of shares (4,000 units at $16.99), increasing direct ownership by 0.55% to 729,735 units (SEC Form 4)4 - Tourmaline Bio, Inc. (0001827506) (Issuer)
- INSIDERThiara Parvinder bought $17,310 worth of shares (1,000 units at $17.31), increasing direct ownership by 1% to 83,782 units (SEC Form 4)4 - Tourmaline Bio, Inc. (0001827506) (Issuer)
- 13D/GSEC Form SC 13G filed by Talaris Therapeutics Inc.SC 13G - Tourmaline Bio, Inc. (0001827506) (Subject)
- 13D/GSEC Form SC 13D/A filed by Talaris Therapeutics Inc. (Amendment)SC 13D/A - Tourmaline Bio, Inc. (0001827506) (Subject)
- 13D/GSEC Form SC 13D/A filed by Talaris Therapeutics Inc. (Amendment)SC 13D/A - Tourmaline Bio, Inc. (0001827506) (Subject)
- SECSEC Form 8-K filed by Talaris Therapeutics Inc.8-K - Tourmaline Bio, Inc. (0001827506) (Filer)
- INSIDERCastelein Caley bought $280,584 worth of shares (20,000 units at $14.03), increasing direct ownership by 4% to 516,519 units (SEC Form 4)4 - Tourmaline Bio, Inc. (0001827506) (Issuer)
- INSIDERThiara Parvinder was granted 75,782 shares (SEC Form 4)4 - Tourmaline Bio, Inc. (0001827506) (Issuer)
TALS FAQ
7 questionsWhat does Talaris Therapeutics Inc. do?
Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, and metabolic disorders. Its lead product candidate is FCR001, a novel allogeneic cell therapy that is in Phase II trial for living donor kidney transplant patients. The company is also developing FCR002 in deceased donor kidney transplants; FCR001 in...Where does TALS stock trade?
Talaris Therapeutics Inc. (TALS) is listed on NASDAQ.What sector and industry is TALS in?
Talaris Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Talaris Therapeutics Inc. go public?
Talaris Therapeutics Inc. (TALS) completed its IPO in 2021.What are analysts saying about TALS?
Talaris Therapeutics Inc. has had 3 recent analyst actions on file. The most recent action was from H.C. Wainwright: Buy with a $1800.00 price target on 2022-10-20. Recent price targets range from $800.00 to $2200.00.What companies are similar to TALS?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare TALS side-by-side with any of them on Quantisnow.How can I track TALS on Quantisnow?
Quantisnow aggregates Talaris Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow TALS to receive live email and push alerts on every new disclosure.